Silverarc Capital Management’s Foghorn Therapeutics FHTX Stock Holding History

Silverarc Capital Management’s Portfolio FHTX Stock Details FHTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$224K	Buy	+45,975	New	+$204K	0.02%	71

Other funds holding FHTX

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Silverarc Capital Management's FHTX Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Foghorn Therapeutics (FHTX) in Q2 2026: 45,975 shares worth $224K. The stake represents 0.02% of the portfolio and ranks #71 among its holdings.

103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

Silverarc Capital Management held 45,975 shares of Foghorn Therapeutics worth $224K as of Q2 2026.
Foghorn Therapeutics was a new Silverarc Capital Management position in Q2 2026.
Foghorn Therapeutics made up 0.02% of Silverarc Capital Management's portfolio in Q2 2026, its #71 holding.
103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.